Published in J Chromatogr on August 01, 1979
Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol (1981) 1.00
Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration. Br J Clin Pharmacol (1980) 0.94
A dose-ranging study to evaluate the beta-adrenoceptor selectivity of single doses of betaxolol. Br J Clin Pharmacol (1990) 0.90
Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man. Br J Clin Pharmacol (1980) 0.84
Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocking agents betaxolol (SL 75212) in healthy volunteers. Br J Clin Pharmacol (1980) 0.83
The effects of time and dose on the relative beta 1- and beta 2-adrenoceptor antagonism of betaxolol and atenolol. Br J Clin Pharmacol (1991) 0.77
Betaxolol and glucose-insulin relationships: studies in normal subjects taking glibenclamide or metformin. Br J Clin Pharmacol (1990) 0.75
Influence of environmental temperature and humidity on bronchial responses during assessment of selectivity of beta-adrenoceptor antagonists in man. Br J Clin Pharmacol (1981) 0.75
Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation (1975) 1.92
N-desmethyldiazepam and amylobarbitone sodium as hypnotics in anxious patients. Plasma levels, clinical efficacy and residual effects. Psychopharmacologia (1975) 1.54
Delayed absorption of phenylbutazone caused by desmethylimipramine in humans. Eur J Pharmacol (1970) 1.47
Hypotensive and renin-suppressing activities of propranolol in hypertensive patients. Clin Sci Mol Med Suppl (1975) 1.46
Zolpidem side-effects. Lancet (1993) 1.37
A sensitive gas chromatographic method for the determination of propranolol in human plasma. J Chromatogr (1973) 1.34
Gas chromatographic method for the determination of nomifensine in human plasma. J Chromatogr (1976) 1.29
Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications. Clin Pharmacokinet (1981) 1.29
Duration between onset and time of obtaining initial treatment among people with anxiety and mood disorders: an international survey of members of mental health patient advocate groups. Psychol Med (2000) 1.26
Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment. Clin Pharmacokinet (1976) 1.25
Effectiveness and pharmacokinetics of indomethacin in premature newborns with patent ductus arteriosus. Eur J Clin Pharmacol (1980) 1.23
Further observations on the interactions between phenobarbital and diphenylhydantoin during chronic treatment in the rat. Biochem Pharmacol (1972) 1.18
Interaction between phenobarbital and diphenylhydantoin in animals and in epileptic patients. Ann N Y Acad Sci (1971) 1.16
Metabolism and Pharmacolinetics of Carbamazepine. Drug Metab Rev (1975) 1.15
Diazepam elimination in premature and full term infants, and children. J Perinat Med (1973) 1.15
Pharmacokinetics of nomifensine in man. Psychopharmacologia (1975) 1.12
Alterations of GABA-mediated synaptic transmission in human epilepsy. Adv Neurol (1986) 1.08
Clincial pharmacokinetics in neonates. Clin Pharmacokinet (1976) 1.07
Prevalence of nightmares and their relationship to psychopathology and daytime functioning in insomnia subjects. Sleep (1997) 1.06
[Acute diltiazem poisoning: kinetic and hemodynamics study]. J Toxicol Clin Exp (1991) 1.03
Monosodium glutamate and the Chinese restaurant syndrome. Nature (1970) 1.02
Simple sensitive and specific gas chromatographic method for the quantification of diltiazem human body fluids. J Chromatogr (1977) 1.01
Quinolinic-phosphoribosyl transferase activity is decreased in epileptic human brain tissue. Epilepsia (1988) 1.01
Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect. Br J Clin Pharmacol (1976) 1.01
Rapid and sensitive method for determination of haloperidol in human samples using nitrogen-phosphorus selective detection. J Chromatogr (1978) 0.99
Studies on plasma protein binding of carbamazepine. Pharmacol Res Commun (1974) 0.97
Biochemical aspects of Huntington's chorea. J Neurol Neurosurg Psychiatry (1977) 0.97
Bioavailability of two carbamazepine preparations during chronic administration to epileptic patients. Epilepsia (1975) 0.95
Further observations on carbamazepine plasma levels in epileptic patients. Relationships with therapeutic and side effects. Neurology (1976) 0.95
EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacology (Berl) (1994) 0.95
Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration. Br J Clin Pharmacol (1980) 0.94
Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol (1996) 0.93
Monoamine acid metabolites and cerebrospinal fluid dynamics in normal pressure hydrocephalus: preliminary results. J Neurol Neurosurg Psychiatry (1975) 0.93
Clinical pharmacokinetics of antiepileptic drugs in adults. Pharmacol Ther (1980) 0.91
Evaluation of memory function in a population of epileptic patients and matched controls. Acta Neurol Scand Suppl (1980) 0.91
Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab Rev (1992) 0.91
A gas chromatographic method for the determination of amantadine in human plasma. J Chromatogr (1972) 0.91
The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice. J Int Med Res (1992) 0.90
Carbamazepine: absorption, distribution, and excretion. Adv Neurol (1975) 0.90
A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol (2002) 0.90
Assessment of the anticholinergic effect of the new antihistamine mizolastine in healthy subjects. Br J Clin Pharmacol (1992) 0.90
Determination of progabide and its main acid metabolite in biological fluids using high-performance liquid chromatography and electrochemical detection. Application to the measurement of blood/plasma partition ratio. J Chromatogr (1984) 0.89
Pharmacodynamics and pharmacokinetics of mizolastine (SL 85.0324), a new nonsedative H1 antihistamine. Ann Allergy (1992) 0.89
Homovanillic acid and 5-hydroxyindole-acetic acid in the csf of patients after a severe head injury. II. Ventricular csf concentrations in acute brain post-traumatic syndromes. Eur Neurol (1975) 0.89
Double-blind crossover trial of progabide versus placebo in severe epilepsies. Epilepsia (1983) 0.88
Infants born to hypertensive mothers treated by acebutolol. Pharmacological studies in the perinatal period. Dev Pharmacol Ther (1982) 0.88
gamma-Aminobutyric acid (GABA) receptor stimulation. I. Neuropharmacological profiles of progabide (SL 76002) and SL 75102, with emphasis on their anticonvulsant spectra. J Pharmacol Exp Ther (1982) 0.88
Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine. Br J Clin Pharmacol (1985) 0.87
A comparison between propranolol, practolol and betaxolol (SL75212) on the circulatory and metabolic responses to insulin-induced hypoglycaemia. Eur J Clin Pharmacol (1981) 0.87
Long-term monitoring of tricyclic antidepressant plasma concentrations. Br J Psychiatry (1980) 0.87
Plasma protein binding of zolpidem in liver and renal insufficiency. Int J Clin Pharmacol Ther Toxicol (1988) 0.86
Beta-blockade and blood-levels after low-dose oral propranolol: The hepatic "first-pass" threshold revisited. Lancet (1978) 0.86
Initiation of and adherence to treatment for mental disorders: examination of patient advocate group members in 11 countries. Med Care (2000) 0.86
Pharmacokinetics of propranolol in normal healthy volunteers. J Pharmacokinet Biopharm (1977) 0.85
The potential use of GABA agonists in psychiatric disorders: evidence from studies with progabide in animal models and clinical trials. Pharmacol Biochem Behav (1983) 0.85
Diurnal variations in steady-state plasma concentrations of valproic acid in epileptic patients. Clin Pharmacokinet (1983) 0.85
The gabaergic hypothesis of depression. Prog Neuropsychopharmacol Biol Psychiatry (1989) 0.85
Beta-adrenoceptor blocking effects and pharmacokinetics of betaxolol (SL 75212) in man. Br J Clin Pharmacol (1980) 0.84
High-performance liquid and gas chromatographic methods for the determination of cicloprolol. J Chromatogr (1990) 0.84
The effect of injections of fluorocitrate into the brains of rats. Biochem Pharmacol (1968) 0.84
Carbamazepine: biotransformation. Adv Neurol (1975) 0.84
Metabolism of exogenous cortisol in humans. I. Diurnal variation in plasma disappearance rate. Biochem Pharmacol (1970) 0.83
Carbamazepine/valproic acid interaction in man and rhesus monkey. Epilepsia (1984) 0.83
Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocking agents betaxolol (SL 75212) in healthy volunteers. Br J Clin Pharmacol (1980) 0.83
Placental transfer to diazepam and its disposition in the newborn. Clin Pharmacol Ther (1975) 0.83
Concentrations of desipramine in the vas deferens and potentiation of noradrenaline response. Br J Pharmacol (1971) 0.83
Therapeutic effects of fengabine, a new GABAergic agent, in depressed outpatients: a double-blind study versus clomipramine. Acta Psychiatr Scand (1990) 0.83
EEG profile of litoxetine after single and repeated administration in healthy volunteers. Br J Clin Pharmacol (1994) 0.82
Zolpidem excretion in breast milk. Eur J Clin Pharmacol (1989) 0.82
GABA and affective disorders. Med Biol (1987) 0.82
Pharmacokinetics of diltiazem after intravenous and oral administration. Eur J Clin Pharmacol (1983) 0.82
A double blind study on the effects of monosodium glutamate in man. Biomedicine (1973) 0.82
Pharmacokinetics and pharmacodynamics of zolpidem following repeated doses in hemodialyzed uraemic patients. Fundam Clin Pharmacol (1993) 0.82
Learning impairment in epileptic patients. Epilepsia (1983) 0.82
Cardiovascular effects of single oral doses of the new beta-adrenoceptor blocker SL 75212 in healthy volunteers [proceedings]. Br J Clin Pharmacol (1979) 0.82
Carbamazepine and carbamazepine-10, 11-epoxide concentrations in human brain. Br J Clin Pharmacol (1977) 0.82
Effects of piribedil on noradrenaline and MOPEG-SO4 levels in the rat brain. Eur J Pharmacol (1974) 0.81
Determination of mephenesin in plasma by high-performance liquid chromatography with fluorimetric detection. J Chromatogr (1990) 0.81
High doses of haloperidol in schizophrenia. A clinical, biochemical, and pharmacokinetic study. Arch Gen Psychiatry (1982) 0.81
A simple and sensitive gas chromatographic method for the determination of clonazepam in human plasma. J Chromatogr (1976) 0.81